Clinical Trial Update: A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment [Phase 1]

View source ↗

Summary

This document updates a Phase 1 clinical trial evaluating belantamab mafodotin in combination with nirogacestat and pomalidomide for relapsed or refractory mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• Nirogacestat (nirogacestat)
• Pomalyst (pomalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING